The landmark Systolic Blood Pressure Intervention Trial (SPRINT) is about to change medical practice.
It showed that more intensive management of hypertension below the commonly recommended blood pressure target significantly improved patient outcomes.
This trial treated blood pressure to achieve a target systolic pressure of 120 millimeters of mercury (mm Hg). Compared to those targeting a systolic pressure of 140 mm Hg, those who were targeted to the lower target had reduced rates of CV events (by around a third) and mortality (by around a quarter), particularly those aged 50 years and older. Those treated to a lower target received an average of three medications for hypertension.
The SPRINT study started in 2009 and includes more than 9,300 participants age 50 and older. It is the largest study of its kind to challenge the currently recommended blood pressure target. The National Institutes of Health, the study’s sponsor, stopped the study earlier than originally planned to fast-tract dissemination.
Note: The SPRINT study did not include patients with diabetes, prior stroke, or polycystic kidney disease.
For more information, click here.
The information and opinions presented here do not necessarily represent the views of the Philippine Heart Association.